Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Technology closer to young patients

Media, Podcast
Technology closer to young patientsG2B

On the occasion of the Rare Diseases Day, our CEO, Meritxell Teixidó, was interviewed by Mari Cruz Hernández Gibert on the “LLETRA LLIGADA” program on Ràdio 4.

In this interview “Technology closer to young patients”, Meritxell explains how G2B offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancer indications such as DIPG. She tells us about the importance of working closely with patients and families. Why she considers that groups such as the KIDS of the Sant Joan de Déu Hospital are necessary for any research project in the field of pediatrics and what it brings her on a personal level to work with this project.

A radio meeting she had the privilege of sharing with Ricard Casanova, a member of KIDS Barcelona and brother of a patient who died of DIPG. A bright young man and a big fan of LEGO who has devised an augmentative communication keyboard in order to help children with illnesses or communication difficulties. An example that regroups many values.

The key is not only to continue researching therapeutic innovation to find cures for these diseases, but also to continue searching, as Ricard does, for ways to provide better care for these patients and their families.

Listen to the interview

Bringing medicines and care beyond barriers!

March 17, 2023/by noticias
Tags: Gate2Brain, pediatricancer
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2023/03/Simple-Motivational-Quote-Instagram-feed-post-4.png 1080 1080 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2023-03-17 15:43:282023-03-20 08:24:06Technology closer to young patients
You might also like
Gate2Brain abre una ronda puenteo de un millón de euros para ensayos preclínicoPlantaDoceGate2Brain opens one million euro bridge round for preclinical trials
Within the framework of the discussion-based interview series, Exploration Science, in which scientists talk about their ventures and areas of expertise, our CEO, Dr. Meritxell Teixidó, and the first and only APS American Peptide Idol joined @CEM's Dr. Wendy Hartsock to discuss the work @Gate2Brain is doing in pediatric oncology, dive into the technology, and talk about empathetic leadership and the power of diversity.CEMExploration Science with Dr. Wendy Harsock
Gate2Brain at TransfiereG2BG2B at Transfiere 2023
¿Cómo transportar fármacos al cerebro para tratar patologías?La VanguardiaHow to transport drugs to the brain to treat pathologies?
THIS IS HOW A DRUG IS TOWED TO THE BRAINExpansiónTHIS IS HOW A DRUG IS TOWED TO THE BRAIN
GATE2BRAIN winner of the Barcelona Activa Pre-acceleration competitionBarcelona ActivaGATE2BRAIN WINNER OF THE BARCELONA ACTIVA PRE-ACCELERATION COMPETITION
Foment shows how the leadership of a new generation of female innovators is already a reality at # MWC21Foment del TreballFoment shows how the leadership of a new generation of female innovators is already a reality at # MWC21
Una tecnología para ayudar a tratar el cáncer infantilgate2brainA technology to help treat pediatric cancer

CATEGORIES

  • Clipping
  • Events
  • Media
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • The innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach”, organized by Foment del Treball.Foment del TreballThe innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach.March 23, 2023 - 08:54
  • G2B at 4YFN 2023G2BGate2Brain at 4YFN-MWC23March 3, 2023 - 08:24
  • Gate2Brain at TransfiereG2BG2B at Transfiere 2023February 17, 2023 - 07:45
  • 📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kidsi4kids Closing Event 2022December 7, 2022 - 12:37
  • WomenStartupAwards, in the "Inspiration" category.WomeninTechSpainFinalist of Women Startup AwardsNovember 15, 2022 - 17:46

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • Barcelona to host BIO-Europe Spring 2024 March 23, 2023 biocat
  • 4YFN 2023 sees record turnout, surpassing all expectations March 6, 2023 biocat
  • European health clusters tackle sector’s main challenges in international framework February 24, 2023 biocat
  • Sector experts review main strategic challenges facing BioRegion of Catalonia February 23, 2023 biocat
  • Different health clusters in Ukraine know about the BioRegion thanks to Biocat February 23, 2023 biocat
  • Biocat and Alira Health launch market access program for BioRegion startups February 23, 2023 biocat
  • CRAASH Barcelona celebrates 5th anniversary February 23, 2023 biocat
  • Highlights: New historic record for investment in the BioRegion, new funding, more acquisitions, and ground-breaking research into strokes February 23, 2023 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Gate2Brain at 4YFN-MWC23G2B at 4YFN 2023G2BThe innovative biopharmaceutical industry, a lever for economic and social well-being. A comprehensive approach”, organized by Foment del Treball.Foment del TreballThe innovative biopharmaceutical industry, a lever for economic and social well-being....
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}